**Supplementary Table S2. Adverse events of any grade. Drug-related serious adverse events by grouped and preferred term and by highest CTCAE grade: concurrent regimen**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **All Grades*****n* (%)** | **Grade 3** ***n* (%)** | **Grade 4*****n* (%)** | **Grade 5*****n* (%)** |
| Total patients treated | 126 (100) | 126 (100) | 126 (100) | 126 (100) |
| Total patients with related serious adverse events | 17 (13) | 12 (10) | 2 (2) | 2 (12) |
| Drug hypersensitivity | 3 (2) | 3 (2) | 0 (0) | 0 (0) |
| Dehydration | 2 (2) | 2 (2) | 0 (0) | 0 (0) |
| Diarrhea | 2 (2) | 1 (1) | 0 (0) | 0 (0) |
| Fatigue | 2 (2) | 0 (0) | 1 (1) | 0 (0) |
| Nausea | 2 (2) | 2 (2) | 0 (0) | 0 (0) |
| Pneumonitis | 2 (2) | 0 (0) | 1 (1) | 1 (1) |
| Vomiting | 2 (2) | 1 (1) | 0 (0) | 0 (0) |
| Abdominal discomfort | 1 (1) | 0 (0) | 0 (0) | 0 (0) |
| Abdominal distension | 1 (1) | 1 (1) | 0 (0) | 0 (0) |
| Back pain | 1 (1) | 1 (1) | 0 (0) | 0 (0) |
| Convulsion | 1 (1) | 1 (1) | 0 (0) | 0 (0) |
| Deep vein thrombosis | 1 (1) | 1 (1) | 0 (0) | 0 (0) |
| Dyspnea | 1 (1) | 0 (0) | 0 (0) | 1 (1) |
| Gastritis | 1 (1) | 0 (0) | 0 (0) | 0 (0) |
| Headache | 1 (1) | 1 (1) | 0 (0) | 0 (0) |
| Hypersensitivity | 1 (1) | 0 (0) | 0 (0) | 0 (0) |
| Hypotension | 1 (1) | 1 (1) | 0 (0) | 0 (0) |
| Hypoxia | 1 (1) | 0 (0) | 0 (0) | 0 (0) |
| Lung infiltration | 1 (1) | 0 (0) | 1 (1) | 0 (0) |
| Aseptic meningitis  | 1 (1) | 1 (1) | 0 (0) | 0 (0) |
| Peripheral edema  | 1 (1) | 1 (1) | 0 (0) | 0 (0) |
| Stomatitisa | 1 (1) | 0 (0) | 0 (0) | 0 (0) |
| Syncope | 1 (1) | 1 (1) | 0 (0) | 0 (0) |

aGrouped terms.

Progression free survival (months)